Acquisition by Amro Albanna of 9404 shares of Aditxt subject to Rule 16b-3
| ADTX Stock | USD 1.67 0.03 1.76% |
Slightly above 63% of Aditxt's investor base is looking to short. The analysis of the overall investor sentiment regarding Aditxt Inc suggests that many traders are alarmed. Aditxt's investing sentiment can be driven by a variety of factors including economic data, Aditxt's earnings reports, geopolitical events, and overall market trends.
Filed transaction by Aditxt Inc director. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Aditxt Fundamental Analysis
We analyze Aditxt's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aditxt using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aditxt based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash And Equivalents
Cash And Equivalents Comparative Analysis
Aditxt is currently under evaluation in cash and equivalents category among its peers. Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Aditxt Inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aditxt stock to make a market-neutral strategy. Peer analysis of Aditxt could also be used in its relative valuation, which is a method of valuing Aditxt by comparing valuation metrics with similar companies.
Peers
Aditxt Related Equities
| UNCY | Unicycive Therapeutics | 3.39 | ||||
| VRAX | Virax Biolabs | 2.94 | ||||
| QNRX | Quoin Pharmaceuticals | 2.23 | ||||
| PALI | Palisade Bio | 2.95 | ||||
| PSTV | Plus Therapeutics | 3.33 | ||||
| DRMA | Dermata Therapeutics | 3.90 | ||||
| ALLR | Allarity Therapeutics | 7.77 | ||||
| BDRX | Biodexa Pharmaceticals | 7.83 | ||||
| REVB | Revelation Biosciences | 19.34 |
Additional Tools for Aditxt Stock Analysis
When running Aditxt's price analysis, check to measure Aditxt's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aditxt is operating at the current time. Most of Aditxt's value examination focuses on studying past and present price action to predict the probability of Aditxt's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aditxt's price. Additionally, you may evaluate how the addition of Aditxt to your portfolios can decrease your overall portfolio volatility.